

Not for release to US wire services or distribution in the United States

Share purchase plan completed

Sydney, Australia – Wednesday, 3 December 2025 – **Radiopharm Theranostics Limited** (ASX:RAD; Nasdaq:RADX), a developer of a world-class platform of radiopharmaceutical products for both diagnostic and therapeutic uses, announced a share purchase plan (**SPP**) on 20 October 2025, and the SPP closed on 28 November 2025.

The SPP raised A\$0.4 million, taking the total raised with the placement announced on 20 October 2025 to A\$35.4 million. Under the SPP, new shares were offered at \$0.03 each. A total of 12,599,991 ordinary shares are scheduled to be issued on Friday 5 December 2025 to SPP participants pursuant to ASX Listing Rule 7.2 Exception 5.

A General Meeting to consider approval of, amongst other matters, the issue of 12,599,991 SPP Attaching Options will be held later today. The SPP Attaching Options will have an exercise price of \$0.039 per option with an expiry date of 31 October 2027. It is intended that the Attaching Options will be issued on Wednesday 10 December 2025 and quoted on the ASX. The full terms of the SPP Attaching Options are annexed to the announcement on 20 October 2025.

The Company would like to thank shareholders who supported the SPP.

Key dates

Event	Date (2025)
EGM for approval of Tranche 2 Placement Shares and Attaching Options	Wednesday, 3 December
Allotment of SPP Shares	Friday, 5 December
Settlement of Tranche 2 Placement Shares	Tuesday, 9 December
Allotment of Tranche 2 Placement Shares and Attaching Options and SPP Attaching Options	Wednesday, 10 December

The Company reserves the right to amend the above timetable, at its discretion, including for the purposes of any Australian Securities and Investments Commission (ASIC) and ASX requirements.

Authorised on behalf of the Radiopharm Theranostics board of directors by Executive Chairman Paul Hopper.

ASX ANNOUNCEMENT
3 December 2025

For more information:

Riccardo Canevari
CEO & Managing Director
P: +1 862 309 0293
E: rc@radiopharmtheranostics.com

Paul Hopper
Executive Chairman
E: paulhopper@lifescienceportfolio.com

Matt Wright
NWR Communications
P: +61 451 896 420
E: matt@nwrcommunications.com.au

Follow Radiopharm Theranostics:

Website – <https://radiopharmtheranostics.com/>

Twitter – <https://twitter.com/TeamRadiopharm>

Linked In – <https://www.linkedin.com/company/radiopharm-theranostics/>

Not an offer of securities

This announcement has been prepared for publication in Australia and may not be released to US wire services or distributed in the United States. This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any securities described in this announcement have not been registered under the US Securities Act of 1933 and may not be offered or sold in the United States except in transactions exempt from, or not subject to, the registration requirements of the US Securities Act and applicable US state securities laws.

Forward-looking statements

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may,' 'should,' 'expect,' 'anticipate,' 'estimate,' 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. Radiopharm does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.